On May 4, 2020, Arcturus Therapeutics and Catalent announced a partnership to support the expected manufacture of Arcturusﾒ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus. LUNAR-COV19 utilizes Arcturusﾒ self-transcribing and replicating mRNA (STARRﾙ) technology and the Companyﾒs LUNARﾮ lipid-mediated delivery to produce an extraordinarily low dose, potential single shot COVID-19 vaccine.